RTP Mobile Logo
Select Publications

Arpino G et al. Final analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer. San Antonio Breast Cancer Symposium 2020;Abstract PD3-02.

Bajorin DF et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). ASCO Genitourinary Cancers Symposium 2021;Abstract 391.

Banerjee S et al. Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. ESMO 2020;Abstract 811MO.

Barcenas CH et al. Bringing diarrhea under CONTROL: Dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer. San Antonio Breast Cancer Symposium 2020;Abstract PS13-20.

Chan A et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer 2020;S1526-8209(20):30258-5. Abstract

Freedman RA et al. Pre- and postoperative neratinib for HER2-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer 2020;20(2):145-51. Abstract

Hamilton E et al. Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study. San Antonio Breast Cancer Symposium 2020;Abstract PD3-07.

Hamilton E et al. Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status. San Antonio Breast Cancer Symposium 2020;Abstract PD3-08.

Herbst RS et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. ASCO 2020;Abstract LBA5.

Holmes FA et al. Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial. San Antonio Breast Cancer Symposium 2020;Abstract PD3-03.

Kelly RJ et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study. ESMO 2020;Abstract LBA9.

Lin NU et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB). ASCO 2020;Abstract 1005.

Modi S et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020;382(7):610-21. Abstract

Modi S et al. Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2020;Abstract PD3-06.

Montemurro F et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol 2020;31(10):1350-8. Abstract

Murthy RK et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 2020;382(7):597-60. Abstract

O’Shaughnessy JA et al. Primary outcome analysis of invasive disease-free survival for monarchE: Abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer. San Antonio Breast Cancer Symposium 2020;Abstract GS1-01.

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Saura C et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial. J Clin Oncol 2020:38(27):3138-49. Abstract

van der Voort A et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial. ASCO 2020;Abstract 501.

von Minckwitz G et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer.  N Engl J Med 2019;380(7):617-28. Abstract

Waks AG et al. The DAPHNe trial: A feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-hp (THP) in HER2-positive breast cancer.  SABCS 2020;Abstract PD3-05.